Close Menu

Thermo Fisher Scientific

New instrumentation, reagents, and methods, as well as increasing interest in small and single-cell samples, could prove a boon for the technology.

New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology.

Bratislava-based HighChem offers software that is used by pharmaceutical and metabolomics laboratories for analyzing complex data and identifying small molecules.

The company announced the collaborations this week in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.

Investigators concluded that the spiked samples from SeraCare were a robust tool for inter-lab comparisons and discussed some areas of discordance seen in the study.

Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.

The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.

The company beat Wall Street expectations on the top and bottom line, and adjusted its guidance for the year upward reflecting the strength of the quarter.

The companies will combine their respective technologies to develop mass spectrometry-based proteomics assays for adverse pregnancy outcomes.

A study from the University of Montreal adds to findings indicating the approach can help reduce sample complexity and interferences in quantitative work.

Pages

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.